Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic ( PK / PD ) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second ( FEV 1 ) in Uncontrolled Moderate‐To‐Severe Asthma
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70057 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Li Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sanofi, Bridgewater, New Jersey, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Asthma, Models, Biological, Anti-Asthmatic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
In this study, we investigated the pharmacokinetic/pharmacodynamic (PK/PD) relationship of dupilumab as an add‐on therapy in the intent‐to‐treat (ITT) uncontrolled moderate‐to‐severe asthma population and identified the factors significantly contributing to variability in forced expiratory volume in 1 second; (FEV 1 ). A semi‐mechanistic population PK/PD model was developed using data from two placebo‐controlled pivotal studies in 2654 adult and adolescent patients ( n = 794 treated with placebo; n = 1860 treated with dupilumab 200 mg [400‐mg loading dose] or 300 mg [600‐mg loading dose] administered subcutaneously every 2 [Q2W] or 4 weeks [Q4W]). Treatment effect was described using a dupilumab concentration‐dependent direct‐response E max model, and placebo effect was described using an empirical time‐dependent function. Demographic variables, baseline disease characteristics, type‐2 inflammation biomarkers, and immunogenicity were tested as covariates using the stepwise forward selection and backward elimination method. Baseline type‐2 inflammation biomarkers (fractional exhaled nitric oxide [FeNO] level and blood eosinophil [EOS] count) were found to be significant covariates for FEV 1 , with greater efficacy in patients with elevated biomarker levels. None of the other tested covariates, including age (12–87 years), had a significant impact on FEV 1 . The PK/PD model predicted near‐maximum FEV 1 response (0.1 L) over a dose of dupilumab. 200–300 mg Q2W in patients with moderate‐to‐severe asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sanofi, Bridgewater, New Jersey, USA.
- Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Zitieren
APA
Zhang, L., Davis, J. D., Kanamaluru, V., & Xu, C. (2025). Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic ( PK / PD ) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second ( FEV 1 ) in Uncontrolled Moderate‐To‐Severe Asthma. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70057
Vancouver
Zhang L, Davis JD, Kanamaluru V, Xu C. Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic ( PK / PD ) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second ( FEV 1 ) in Uncontrolled Moderate‐To‐Severe Asthma. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70057
BibTeX
@article{Zhang2025,
author = {Zhang, Li and Davis, John D and Kanamaluru, Vanaja and Xu, Christine},
title = {Semi‐Mechanistic Population Pharmacokinetic/Pharmacodynamic ( PK / PD ) Modeling of Dupilumab on Pre‐Bronchodilator Forced Expiratory Volume in 1 Second ( FEV 1 ) in Uncontrolled Moderate‐To‐Severe Asthma},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70057}
}
EUVIMED